Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy (NCT05887661) | Clinical Trial Compass
RecruitingNot Applicable
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
China100 participantsStarted 2022-05-01
Plain-language summary
The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are:
1. The safety and feasibility of HP
2. To evaluate whether HP can reduce perioperative blood transfusion ratio Participants undergoing liver resection with HP was performed by the anesthesiologist. Blood was withdrawn approximately 30 min prior to the initiation of liver parenchymal transection from central venous. The aim was to maintain the CVP between 0 to 5 cmH2O. HP volume was 5-10 mL/kg of patient body weight, generally. Participants in control group undergoing liver resection without HP.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinical diagnosis of Hepatocellular Carcinoma
* Preference for laparoscopic hepatectomy and patient agreement
Exclusion Criteria:
* Age \<18 years
* Pregnancy
* Refusal of blood product transfusion
* Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
* History of significant cerebrovascular disease
* Restrictive or obstructive pulmonary disease
* Uncontrolled hypertension
* Renal dysfunction (glomerular filtration rate \<60 mL/min),
* Hemoglobin \<100 g/L
* Abnormal coagulation values (international normalized ratio \>1.5 not on warfarin and/or platelet count \<100 ×109/L)
* Evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L)
* Presence of active infection
* Preoperative autologous blood donation
* Patients were not allowed to receive erythropoietin at any time during the index hospitalization.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The proportion of allogeneic red blood cell products transfusion
Timeframe: From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months.
Trial details
NCT IDNCT05887661
SponsorThe First Affiliated Hospital with Nanjing Medical University